Colorectal cancer immunotherapy: what COMMIT changes

Colorectal cancer immunotherapy is already a standard first-line approach for tumors with a particular molecular feature: deficient DNA mismatch repair and high microsatellite instability, or dMMR/MSI-H. Yet some of these cancers still progress early on checkpoint blockade. The COMMIT trial asked whether adding chemotherapy and an anti-VEGF drug from the start could reduce that risk.

There is a biological reason these tumors often respond well to immunotherapy. When DNA mismatch repair is defective, cancer cells accumulate more copying errors and therefore more mutations. Those mutations can generate abnormal proteins that make the tumor easier for the immune system to recognize. Checkpoint inhibitors remove some of the inhibitory signals that normally restrain T cells, allowing them to attack more effectively.

What COMMIT compared

COMMIT was a multicenter, open-label, randomized study. It originally assigned patients among three first-line strategies: mFOLFOX6 chemotherapy plus bevacizumab, atezolizumab alone, or the combination of mFOLFOX6, bevacizumab and atezolizumab. After KEYNOTE-177 established immunotherapy as a first-line standard for dMMR/MSI-H disease, the chemotherapy-only arm was closed after 20 patients had been enrolled.

The main comparison therefore involved two groups of 41 patients each: atezolizumab alone versus atezolizumab with mFOLFOX6 and bevacizumab. Median follow-up was 46 months.

The difference in the primary endpoint was substantial. The hazard ratio for progression or death was 0.439 in favor of the combination. The objective response rate was 86.1% with combination therapy versus 46% with atezolizumab alone. At 12 months, disease control was maintained in 64.7% and 32.4% of patients, respectively.

Early disease control was particularly notable. Progressive disease as the best response was uncommon in the combination arm but much more frequent with atezolizumab alone. That raises one of the study’s most interesting questions: could chemotherapy and VEGF blockade provide immediate tumor control while immunotherapy is still taking effect in patients otherwise at risk of early progression?

Why the combination may have worked better

mFOLFOX6 directly damages rapidly dividing cancer cells. Bevacizumab blocks VEGF, a signal tumors use to support new blood-vessel growth. In theory, this may do more than shrink tumor burden: it may also alter the tumor microenvironment in ways that make immune attack more effective.

But COMMIT cannot prove that the three components were truly synergistic at the immune level. A simpler explanation is also possible: chemotherapy may have controlled tumor cells during the period before atezolizumab produced an effective immune response. In addition, dMMR/MSI-H status was determined locally rather than through mandatory central confirmation. A tumor misclassified as dMMR could respond poorly to immunotherapy while remaining sensitive to chemotherapy.

The cost of treatment intensification was clear. Grade 3 or higher adverse events occurred in 34 of 41 patients in the combination arm and 18 of 41 patients receiving atezolizumab alone—about 83% versus 44%. At the same time, there was no statistically significant improvement in overall survival. The study was not powered to provide a definitive answer on survival.

Why this does not redefine first-line treatment

COMMIT opened in 2017, and the treatment landscape changed substantially while the trial was running. Current first-line standards for confirmed dMMR/MSI-H metastatic colorectal cancer include PD-1 blockade such as pembrolizumab and dual immunotherapy with nivolumab plus ipilimumab. COMMIT compared its combination with neither of these modern standards. Its control arm used atezolizumab, a PD-L1 inhibitor.

The conclusion is therefore narrower than the headline PFS result may suggest. Adding mFOLFOX6 and bevacizumab to atezolizumab improved disease control and prolonged progression-free survival compared with atezolizumab alone. But it also produced substantially more severe toxicity and did not demonstrate an overall-survival advantage.

The study is most useful for the question it leaves open. Some patients at high risk of early progression may ultimately benefit from a more intensive first-line strategy. Identifying those patients—and determining whether chemotherapy should be added to an effective modern PD-1 backbone—will require new trials with rigorous molecular confirmation and direct comparison against current standards.